A Exploratory Clinical Study on the Predictive Analysis of Multiomics analysis for the Efficacy of Combination Therapy with Finasteride and Tamsulosin in Benign Prostatic Hyperplasia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400081646

Enrollment

Unknown

Registered

2024-03-07

Start date

2024-04-01

Completion date

Unknown

Last updated

2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Hyperplasia

Interventions

Case series:None

Eligibility

Sex/Gender

Male

Age

50 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 50 years or older. 2. Patients with clear symptoms of benign prostatic hyperplasia (BPH) that meet the diagnostic criteria for BPH. 3. Patients who meet the indications for combined treatment with finasteride and tamsulosin for BPH. 4. Subjects who fully understand the patient information, declare their compliance with the study procedures, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to MRI enhancement; 2. Patients who are intolerant to finasteride and tamsulosin or experience significant side effects; 3. Patients with a confirmed diagnosis of prostate cancer.

Design outcomes

Primary

Measure	Time frame
PI-RADs score of Enhanced MRI of the prostate;MRI volume reduction rate after 6 months of medication, Changes in the proportion of multiple histological types before and after medication;	—

Secondary

Measure	Time frame
Age;Urine flow rate (Qmax);Prostate-specific antigen;International prostate symptom score;	—

Countries

China

Contacts

Public ContactBin Xu

Shanghai Ninth People's Hospital

chxb2004@126.com+86 133 8627 1601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026